Author

Ben Sprangers

Universitair Ziekenhuis LeuvenORCID 0000-0003-1314-9675Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:GWAS / association mapping· 1 Assay:GWAS summary statistics· 1 Assay:protein structure· 1 Approach:statistical model· 1

Frequent Co-Authors

Adele MitrottiiD· 1 shared Aftab S. ChishtiiD· 1 shared Akchurin Oleh· 1 shared Alejandro Quiroga· 1 shared Andrea Magnano· 1 shared Andrew S. BombackiD· 1 shared Antonello Pani· 1 shared Antonio AmorosoiD· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetic & Genomic Medicine

Adele MitrottiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic & Genomic MedicinemedRxivPreprintNov 19, 2021

GWAS defines pathogenic signaling pathways and prioritizes drug targets for IgA nephropathy

Krzysztof Kiryluk, Elena Sánchez, Shu‐Feng Zhou…·Claudia Izzi

This study identifies 30 genome-wide significant risk loci for IgA nephropathy, links them to inflammatory pathways, and prioritizes drug targets.

5 citations

humanGWAS summary statistics

𝕏 PostBluesky

BioinformaticsPLoS ONEPeer-reviewedMay 27, 2020

Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor

Melissa F. Adasme, Daniele Parisi, Kristien Van Belle…·Michael Schroeder

This paper identifies ibrutinib as a VEGFR2 inhibitor through structure-based drug repositioning, revealing its polypharmacological action beyond BTK.

29 citations

humanprotein structure

𝕏 PostBluesky